康霈生技股份有限公司

Caliway is delighted to shared that CBL-514 Phase 2b study (CBL-0204) has met all the primary and secondary endpoints, with over 80% of participants in the PP population achieved at least 1-grade improvement using clinician reported- and patient reported- Abdominal Fat Rating Scale. This news marks a significant milestone in paving its way to global Phase 3 study, and shades to becoming the first injectable for the large area fat reduction. #caliway #cbl514 #fatreduction #medicalaesthetics #phase2b

 Caliway (TWSE-6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index. #TWSE #Caliway

Caliway is pleased announce that CBL-514 has been granted another Orphan Drug Designation (#ODD) by EMA, after receiving Fast Track Designation and ODD for Dercum's disease treatment from the U.S. FDA earlier this year. #OrphanDrug #CBL514 #dercumsdisease #EMA

Caliway has completed the last of the two CBL-514 #Phase2b studies for fat reduction (CBL-0205), marking a significant milestone in our journey to bring this #innovative product to market, as the possible success of two Phase 2b studies meeting endpoints will make CBL-514 the first #fatreduction product for large area to enter the Phase 3 study. #cbl514 #caliway

Caliway is pleased to announce the successful public listing on Taipei Exchange and the completion of #IPO! The round marked the largest IPO in Taiwan's biotech industry history. #TWSE #IPO #Caliway

Caliway is excited to share that the subject recruitment of CBL-514 Phase 2b study for Dercum’s disease has been initiated, marking a milestone in our journey to deliver treatment for this challenging #raredisease. #cbl514 #dercumsdisease #phase2b

Caliway is delighted to share that CBL-514's Phase 2b study for subcutaneous fat reduction, CBL-0204, was completed! #Caliway #cbl514 #fatreduction #medicalaesthetic #phase2b

Caliway is delighted to share that we are one of the 200 companies that are going to present at the upcoming BIO 2024 in San Diego! Our session is on Wednesday, June 5 at 11:45 AM in Company Presentation Theater 2. Look forward to seeing you there! #BIO2024

Caliway's first Phase 2 study results announcement in 2024! CBL-0201EFP Phase 2 study demonstrated CBL-514 statistically significant efficacy in reducing #cellulite severity scores at 4 and 12 weeks after treatment, moreover, over 50% of participants experienced at least 1 level of improvement in cellulite severity. For detailed topline results, please visit:

Caliway is going to be one of the exhibitors at FDRS 2024 from April 19-21 at the Marriott St. Louis Airpot Hotel in St. Louis, MO! FDRS 2024 includes surgical and non-surgical treatment options in managing lipedema, Dercum's disease, and Madelung's disease.  For more information about FDRS: #FDRS2024 #FDRS #dercumsdisease #dercumdisease